Cagrisema Combination Therapy Shows Superior Weight Loss and Metabolic Benefits

Obesity is a chronic, progressive disease associated with numerous health complications, including type 2 diabetes, cardiovascular disease, and certain cancers. Semaglutide, a GLP-1 receptor agonist, has emerged as a highly effective medication for weight management. However, there's an ongoing need for even more potent and comprehensive anti-obesity treatments. This systematic review and meta-analysis aimed to directly compare the efficacy and safety of novel agents, cagrilintide and cagrisema, against semaglutide monotherapy to identify potentially superior therapeutic options.

The comprehensive analysis revealed that cagrisema demonstrated significantly greater body weight reduction compared to both semaglutide and cagrilintide monotherapies. Patients treated with cagrisema achieved an average body weight reduction of -18.5% (95% CI: -19.2% to -17.8%), which was a substantial 5.2 percentage points greater than semaglutide alone (-13.3%, 95% CI: -14.0% to -12.6%; p<0.001). For comparison, cagrilintide monotherapy resulted in a -10.1% weight reduction. > The most striking finding was that cagrisema led to 3.5-fold higher odds of achieving ≥15% body weight loss compared to semaglutide monotherapy (OR 3.5, 95% CI: 2.8-4.3; p<0.001). Regarding safety, adverse events, predominantly gastrointestinal (nausea, diarrhea), were slightly more frequent with cagrisema but generally mild to moderate, with discontinuation rates due to adverse events being comparable across groups (cagrisema 8.1% vs semaglutide 7.5%; p=0.21). Furthermore, cagrisema significantly improved glycemic control, evidenced by an HbA1c reduction of -1.8% compared to -1.3% for semaglutide (p<0.001).